

Pembrolizumab KEYNOTE-045

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects



Other adjustments



Pembrolizumab KEYNOTE-045

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Genitourinary Cancers  
Therapeutic Indication: Locally advanced or metastatic UC in adults who have received prior platinum-containing ChT  
Experimental Arm: Pembrolizumab  
Control Arm: Investigator's choice of ChT (paclitaxel, docetaxel or vinflunine)

